Cover Image

Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1highCD11b+ cells elimination in hepatocellular carcinoma

Cryoablation (CRA) and microwave ablation (MWA) are two main local treatments for hepatocellular carcinoma (HCC). However, which one is more curative and suitable for combining with immunotherapy is still controversial. Herein, CRA induced higher tumoral PD-L1 expression and more T cells infiltratio...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jizhou Tan (Author), Ting Liu (Author), Wenzhe Fan (Author), Jialiang Wei (Author), Bowen Zhu (Author), Yafang Liu (Author), Lingwei Liu (Author), Xiaokai Zhang (Author), Songling Chen (Author), Haibiao Lin (Author), Yuanqing Zhang (Author), Jiaping Li (Author)
Format:	Book
Published:	Elsevier, 2023-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023)

Product review on the Anti-PD-L1 antibody atezolizumab
by: Neil J. Shah, et al.
Published: (2018)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020)

Product review: avelumab, an anti-PD-L1 antibody
by: Julie M. Collins, et al.
Published: (2019)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
by: He YY, et al.
Published: (2018)

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
by: Yosuke Shibata, et al.
Published: (2023)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
by: Faiena I, et al.
Published: (2018)

A mouse pancreatic organoid model to compare PD-L1 blocking antibodies
by: Guangyuan Li, et al.
Published: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021)

Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1
by: Nishant Mohan, et al.
Published: (2022)

Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer
by: Hsuan‐Chen Liu, et al.
Published: (2023)

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
by: Pauline Malinge, et al.
Published: (2024)

Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the 'Real-Life' Setting
by: Moran Gadot, et al.
Published: (2022)

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N)
by: Jing Ma, et al.
Published: (2018)

Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
by: Chen Chen, et al.
Published: (2021)

Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering?
by: Andrea Zanello, et al.
Published: (2022)

Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China
by: Zhou D, et al.
Published: (2023)

A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors
by: Yongming Chen, et al.
Published: (2024)

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
by: Fabian Krutzek, et al.
Published: (2022)

PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019)

The Prognostic and Therapeutic Value of PD-L1 in Glioma
by: Ruo Qiao Chen, et al.
Published: (2019)

Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy
by: Terufumi Kubo, et al.
Published: (2021)

Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy
by: Baijia Jiang, MD, et al.
Published: (2018)

PD-L1 dimerisation induced by biphenyl derivatives mediates anti-breast cancer activity via the non-immune PD-L1-AKT-mTOR/Bcl2 pathway
by: Hua Zhang, et al.
Published: (2023)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
by: Chengliang Sun, et al.
Published: (2022)

The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface
by: Matyas Meggyes, et al.
Published: (2019)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
by: Laura Jimbu, et al.
Published: (2021)

PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC
by: Xiao Wang, et al.
Published: (2020)

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
by: Yanhua Bai, et al.
Published: (2017)

Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy
by: Irene Tang, et al.
Published: (2023)

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia
by: Yingying Wang, et al.
Published: (2018)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018)

Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer
by: Xumin Zhou, et al.
Published: (2022)

Meningiomas and the tumor microenvironment: expression of PD-L1 and expression of PD-L1 and interferon-gamma in the prognosis
by: Gunter Gerson, et al.

Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells
by: Manuel A Silva, et al.
Published: (2020)

Comparing Model Performance in Characterizing the PK/PD of the Anti‐Myostatin Antibody Domagrozumab
by: Abhinav Tiwari, et al.
Published: (2020)

MALARIAL ANTIBODIES AND GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G-6-PD) DEFICIENCY
by: Gh.H.Edrissian, et al.
Published: (1983)